ECSP17075380A - Fusiones de variante iii del receptor de factor de crecimiento epidérmico-mesotelina y métodos para usar los mismos - Google Patents
Fusiones de variante iii del receptor de factor de crecimiento epidérmico-mesotelina y métodos para usar los mismosInfo
- Publication number
- ECSP17075380A ECSP17075380A ECIEPI201775380A ECPI201775380A ECSP17075380A EC SP17075380 A ECSP17075380 A EC SP17075380A EC IEPI201775380 A ECIEPI201775380 A EC IEPI201775380A EC PI201775380 A ECPI201775380 A EC PI201775380A EC SP17075380 A ECSP17075380 A EC SP17075380A
- Authority
- EC
- Ecuador
- Prior art keywords
- methods
- mesothelin
- growth factor
- factor receptor
- epidermal growth
- Prior art date
Links
- 102000009024 Epidermal Growth Factor Human genes 0.000 title 1
- 101800003838 Epidermal growth factor Proteins 0.000 title 1
- 229940116977 epidermal growth factor Drugs 0.000 title 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 title 1
- 102000037865 fusion proteins Human genes 0.000 abstract 3
- 108020001507 fusion proteins Proteins 0.000 abstract 3
- 230000028993 immune response Effects 0.000 abstract 2
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 102000001301 EGF receptor Human genes 0.000 abstract 1
- 108060006698 EGF receptor Proteins 0.000 abstract 1
- 102000003735 Mesothelin Human genes 0.000 abstract 1
- 108090000015 Mesothelin Proteins 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001104—Epidermal growth factor receptors [EGFR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001111—Immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001166—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
- A61K39/001168—Mesothelin [MSLN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- General Chemical & Material Sciences (AREA)
- Pulmonology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
En el presente documento se proporcionan composiciones y métodos para desencadenar una respuesta inmunitaria en un sujeto. En particular, la presente divulgación se refiere a proteínas de fusión que comprenden un polipéptido de la variante III del receptor de factor de crecimiento epidérmico (EGFRvIII) y un polipéptido de mesotelina, y a métodos para desencadenar una respuesta inmunitaria usando células hospedadoras que comprenden moléculas de ácido nucleico que codifican dichas proteínas de fusión. En algunas realizaciones, las moléculas de ácido nucleico pueden codificar una proteína de fusión EGFRvIII-mesotelina que comprende una secuencia de aminoácidos que es al menos i) un 90% idéntica, ii) un 95% idéntica, o iii) un 99% idéntica a EGFRvIIIx5-mesotelina35-622 tal como se expone en la SEQ ID NO: 8.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562146559P | 2015-04-13 | 2015-04-13 | |
| US201562243397P | 2015-10-19 | 2015-10-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP17075380A true ECSP17075380A (es) | 2018-02-28 |
Family
ID=55809232
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECIEPI201775380A ECSP17075380A (es) | 2015-04-13 | 2017-11-13 | Fusiones de variante iii del receptor de factor de crecimiento epidérmico-mesotelina y métodos para usar los mismos |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US10105427B2 (es) |
| EP (1) | EP3283509A1 (es) |
| JP (1) | JP6782253B2 (es) |
| KR (1) | KR20180002640A (es) |
| CN (1) | CN107750256A (es) |
| AU (1) | AU2016247887A1 (es) |
| BR (1) | BR112017022076A2 (es) |
| CA (1) | CA2982533A1 (es) |
| CO (1) | CO2017011431A2 (es) |
| CR (1) | CR20170507A (es) |
| EA (1) | EA201792274A1 (es) |
| EC (1) | ECSP17075380A (es) |
| HK (2) | HK1250992A1 (es) |
| IL (1) | IL254957A0 (es) |
| MA (1) | MA44379A (es) |
| MX (1) | MX2017013174A (es) |
| PH (1) | PH12017502080A1 (es) |
| SG (1) | SG11201708360TA (es) |
| SV (1) | SV2017005545A (es) |
| TW (1) | TW201710285A (es) |
| UY (1) | UY36616A (es) |
| WO (1) | WO2016168198A1 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107750256A (zh) | 2015-04-13 | 2018-03-02 | 艾杜罗生物科技公司 | 表皮生长因子受体变体iii‑间皮素融合物及其使用方法 |
| JP2018512165A (ja) | 2015-04-13 | 2018-05-17 | アデュロ バイオテック，インコーポレイテッド | 癌の治療のための免疫原性融合タンパク質 |
| US20170199961A1 (en) | 2015-12-16 | 2017-07-13 | Gritstone Oncology, Inc. | Neoantigen Identification, Manufacture, and Use |
| ES3029080T3 (en) | 2017-10-10 | 2025-06-23 | Seattle Project Corp | Neoantigen identification using hotspots |
| US11885815B2 (en) | 2017-11-22 | 2024-01-30 | Gritstone Bio, Inc. | Reducing junction epitope presentation for neoantigens |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5830702A (en) | 1990-10-31 | 1998-11-03 | The Trustees Of The University Of Pennsylvania | Live, recombinant listeria monocytogenes and production of cytotoxic T-cell response |
| US7635479B2 (en) | 2000-03-29 | 2009-12-22 | The Trustees Of The University Of Pennsylvania | Composition and methods for enhancing immunogenecity of antigens |
| US6051237A (en) | 1994-11-08 | 2000-04-18 | The Trustees Of The University Of Pennsylvania | Specific immunotherapy of cancer using a live recombinant bacterial vaccine vector |
| DE69532767T2 (de) | 1994-11-28 | 2004-08-12 | Thomas Jefferson University | Peptid umfassend eine Sequenz aus einer Fusionsverbindungsstelle in einem mutierten EGF-Rezeptor vom Typ III |
| WO2004006837A2 (en) | 2002-07-12 | 2004-01-22 | The Johns Hopkins University | Mesothelin vaccines and model systems |
| JP2006514823A (ja) | 2002-08-20 | 2006-05-18 | ミレニアム ファーマスーティカルズ インク | 子宮頸癌の同定、評価、予防および治療を行うための組成物、キットおよび方法 |
| JP4545151B2 (ja) | 2003-02-06 | 2010-09-15 | シーラス コーポレイション | 非食細胞中への侵入について減弱化されているリステリア、そのリステリアを含むワクチン、およびそれらの使用法 |
| WO2004084936A2 (en) | 2003-02-06 | 2004-10-07 | Cerus Corporation | Modified free-living microbes, vaccine compositions and methods of use thereof |
| JP5283335B2 (ja) | 2003-06-17 | 2013-09-04 | マンカインド コーポレイション | 各種癌の治療を目的とした腫瘍関連抗原の組合せ |
| US7935804B2 (en) | 2006-03-01 | 2011-05-03 | Aduro Biotech | Engineered Listeria and methods of use thereof |
| JP5347135B2 (ja) * | 2006-03-01 | 2013-11-20 | アドゥロ バイオテック | 遺伝子工学操作されたｌｉｓｔｅｒｉａおよびその使用方法 |
| WO2007117371A2 (en) | 2006-03-01 | 2007-10-18 | Anza Therapeutics, Inc. | Engineered listeria and methods of use thereof |
| SI2640842T1 (sl) | 2010-11-17 | 2018-09-28 | Aduro Biotech, Inc. | Postopki in sestavki za induciranje imunskega odziva na EGFRvIII |
| SG11201502792TA (en) * | 2012-12-27 | 2015-05-28 | Aduro Biotech Inc | Signal peptide fusion partners facilitating listerial expression of antigenic sequences and methods of preparation and use thereof |
| CN104211814A (zh) * | 2013-05-29 | 2014-12-17 | 三星电子株式会社 | 用于消耗靶膜蛋白的组合物 |
| JP2018512165A (ja) | 2015-04-13 | 2018-05-17 | アデュロ バイオテック，インコーポレイテッド | 癌の治療のための免疫原性融合タンパク質 |
| CN107750256A (zh) | 2015-04-13 | 2018-03-02 | 艾杜罗生物科技公司 | 表皮生长因子受体变体iii‑间皮素融合物及其使用方法 |
-
2016
- 2016-04-12 CN CN201680028967.8A patent/CN107750256A/zh active Pending
- 2016-04-12 MX MX2017013174A patent/MX2017013174A/es unknown
- 2016-04-12 KR KR1020177031486A patent/KR20180002640A/ko not_active Withdrawn
- 2016-04-12 UY UY0001036616A patent/UY36616A/es not_active Application Discontinuation
- 2016-04-12 MA MA044379A patent/MA44379A/fr unknown
- 2016-04-12 US US15/097,178 patent/US10105427B2/en not_active Expired - Fee Related
- 2016-04-12 HK HK18110280.8A patent/HK1250992A1/zh unknown
- 2016-04-12 CA CA2982533A patent/CA2982533A1/en not_active Abandoned
- 2016-04-12 WO PCT/US2016/027136 patent/WO2016168198A1/en not_active Ceased
- 2016-04-12 AU AU2016247887A patent/AU2016247887A1/en not_active Abandoned
- 2016-04-12 SG SG11201708360TA patent/SG11201708360TA/en unknown
- 2016-04-12 EP EP16718812.7A patent/EP3283509A1/en not_active Withdrawn
- 2016-04-12 TW TW105111337A patent/TW201710285A/zh unknown
- 2016-04-12 JP JP2017554395A patent/JP6782253B2/ja not_active Expired - Fee Related
- 2016-04-12 HK HK18110071.1A patent/HK1250730A1/zh unknown
- 2016-04-12 CR CR20170507A patent/CR20170507A/es unknown
- 2016-04-12 EA EA201792274A patent/EA201792274A1/ru unknown
- 2016-04-12 BR BR112017022076-8A patent/BR112017022076A2/pt not_active Application Discontinuation
-
2017
- 2017-10-09 IL IL254957A patent/IL254957A0/en unknown
- 2017-10-13 SV SV2017005545A patent/SV2017005545A/es unknown
- 2017-11-07 CO CONC2017/0011431A patent/CO2017011431A2/es unknown
- 2017-11-13 EC ECIEPI201775380A patent/ECSP17075380A/es unknown
- 2017-11-16 PH PH12017502080A patent/PH12017502080A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2018512166A (ja) | 2018-05-17 |
| HK1250992A1 (zh) | 2019-01-18 |
| EP3283509A1 (en) | 2018-02-21 |
| CO2017011431A2 (es) | 2018-01-16 |
| MA44379A (fr) | 2019-01-23 |
| HK1250730A1 (zh) | 2019-01-11 |
| BR112017022076A2 (pt) | 2018-08-14 |
| AU2016247887A1 (en) | 2017-11-02 |
| US10105427B2 (en) | 2018-10-23 |
| EA201792274A1 (ru) | 2018-02-28 |
| UY36616A (es) | 2016-10-31 |
| IL254957A0 (en) | 2017-12-31 |
| TW201710285A (zh) | 2017-03-16 |
| CA2982533A1 (en) | 2016-10-20 |
| JP6782253B2 (ja) | 2020-11-11 |
| WO2016168198A1 (en) | 2016-10-20 |
| SG11201708360TA (en) | 2017-11-29 |
| KR20180002640A (ko) | 2018-01-08 |
| PH12017502080A1 (en) | 2018-05-07 |
| MX2017013174A (es) | 2018-04-11 |
| US20160346369A1 (en) | 2016-12-01 |
| CN107750256A (zh) | 2018-03-02 |
| CR20170507A (es) | 2018-02-13 |
| SV2017005545A (es) | 2018-05-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX388739B (es) | Casetes optimizados de expresión del gen humano del factor viii de coagulación y su uso. | |
| ECSP17075380A (es) | Fusiones de variante iii del receptor de factor de crecimiento epidérmico-mesotelina y métodos para usar los mismos | |
| CO2017010807A2 (es) | Enzimas y aplicaciones de las mismas | |
| MX389093B (es) | Composiciones y metodos para la glicosilacion de proteinas. | |
| BR112019004711A2 (pt) | receptores de antígeno quiméricos compreendendo domínios de fibronectina tipo iii específicos para bcma e usos dos mesmos | |
| AR102950A1 (es) | Variantes de lipasa y polinucleótidos que las codifican | |
| BR112017003406A2 (pt) | genoma de chromobacterium subtsugae | |
| ES2531290T3 (es) | Transferasas y oxidorreductasas, ácidos nucleicos que las codifican y métodos para prepararlas y usarlas | |
| MX2017004664A (es) | Conjugados de farmacos de anticuerpos modificados mediante glicoingenieria. | |
| EA201691111A1 (ru) | Химерные белки фактора viii и их применение | |
| MX375778B (es) | Variantes mejoradas de enzimas. | |
| AR110093A1 (es) | D-psicosa 3-epimerasa y método para preparar d-psicosa utilizando la misma | |
| AR102445A1 (es) | COMPOSICIONES Y MÉTODOS RELACIONADOS CON b-GLUCOSIDASA | |
| CO2023003453A2 (es) | Proteínas de fusión inmunogénicas de coronavirus y métodos relacionados | |
| MX2020012649A (es) | Neoantígenos especificos de tumor y métodos de uso de estos. | |
| MX2020001058A (es) | Marcadores de fusión para expresión de proteínas recombinantes. | |
| MX2018003445A (es) | Expresion de proteinas que contienen fc. | |
| MX2022008298A (es) | Anticuerpo para sesgar proporciones de sexos y metodos de uso del mismo. | |
| CU20200064A7 (es) | Expresión de la proteína de superficie neumocócica a (pspa) | |
| AR110626A1 (es) | Paramixovirus y sus usos | |
| AR105615A1 (es) | Fusiones de variante iii del receptor de factor de crecimiento epidérmico-mesotelina y métodos para usar los mismos | |
| AR094105A1 (es) | Metodo para aumentar la resistencia a los patogenos en las plantas | |
| CU20220017A7 (es) | Secuencia de extensión n-terminal para la expresión de péptidos terapéuticos recombinantes | |
| AR104231A1 (es) | Proteínas de fusión inmunogénicas para el tratamiento del cáncer | |
| AR104475A1 (es) | Polipéptidos fgf-21 modificados y sus usos |